SOURCE: Adeona Pharmaceuticals, Inc.

November 13, 2008 09:31 ET

Adeona Pharmaceuticals to Provide Clinical Update and Report Third Quarter 2008 Results

ANN ARBOR, MI--(Marketwire - November 13, 2008) - Adeona Pharmaceuticals, Inc. (AMEX: AEN), a specialty pharmaceutical company developing innovative clinical stage drug candidates for the treatment of autoimmune and central nervous system (CNS), announced that it will host a teleconference call at 4:00 p.m. EST tomorrow to discuss the financial results. Adeona will also provide a review of the Company's clinical pipeline. There will be a question-and-answer session directly following the presentation of the results.

About Adeona Pharmaceuticals, Inc.

Adeona Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is developing proprietary, drug candidates for the treatment of autoimmune and central nervous system diseases. Adeona's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and to complete the further clinical testing, manufacturing, regulatory requirements and seek marketing authorizations. Adeona is focused on treating rheumatoid arthritis (RA), dry age-related macular degeneration (AMD), multiple sclerosis (MS), and fibromyalgia. For further information, please visit www.adeonapharma.com.

Contact Information

  • For Further Information, Contact:

    Nicholas Stergis
    Chief Executive Officer
    734-332-7800

    Thomas Redington (Investor Relations)
    Redington Inc.
    203-222-7399
    www.redingtoninc.com